Is BPC-157 Legal in Kentucky? Federal Framework, State Rules, and How to Get It

Print or save as PDF

See the public record for BPC-157

What is BPC-157's federal status?

BPC-157 is a synthetic peptide of 15 amino acids, made as a free base or as an acetate salt that FDA treats as two different bulk substances. No FDA-approved drug contains it, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

Can a Kentucky pharmacy compound it?

FDA's list of bulk substances nominated for state-licensed pharmacies and physicians, updated May 14, 2026, carries BPC-157 in none of its three categories, so category 1 (the group FDA generally will not act against compounders for if conditions are met) does not cover it [2]. It sat in category 2, substances that may present significant safety risks, from September 2023 until April 22, 2026. It then moved to a 'nominated but withdrawn' table after the nominating groups withdrew, not because FDA cleared it [5]. FDA's stated concerns remain on that page: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration', and FDA 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [5].

FDA's reviewers recommended against listing it in July 2026, citing poor chemical characterization, little safety and immunogenicity data, and insufficient evidence for ulcerative colitis, the use FDA evaluated [1]. On July 23, 2026 FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the list, against FDA staff's recommendation; news reports give the vote as 8 to 6 with 1 abstention. The vote is advice only. BPC-157 is not on the list, and adding it would require formal rulemaking [8][4].

What does the October 2026 HHS draft policy say?

On October 28, 2026 HHS filed notice of a draft enforcement-discretion policy covering six peptides, BPC-157 among them. It is scheduled for Federal Register publication on October 30, 2026, with public comment open for two weeks after publication [3]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the conditions are met [3].

For BPC-157 the conditions include:

• the acetate form only;
• subcutaneous, intramuscular, oral or topical forms, with nasal, rectal and intravenous not listed;
• a single active ingredient;
• bulk substance from an FDA-registered manufacturer with a valid certificate of analysis meeting a peptide testing standard;
• a label reading 'This is a compounded drug product. Not for resale.';
• a patient-specific prescription;
• serious adverse events and quality problems reported to FDA MedWatch;
• only an FDA 510(k)-cleared syringe as a co-packaged device;
• documentation of adequate bioavailability for oral forms [4].

The notice does not place BPC-157 on any list. It says the policy 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it, for example if a safety signal or product quality issue appears [3]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities, and BPC-157 is not on FDA's list for outsourcing facilities (updated March 21, 2025) [3][9]. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before marketing [9].

Does federal policy settle Kentucky legality?

No. The federal records cited here do not establish that a Kentucky pharmacy may compound or dispense BPC-157. BPC-157 is in none of FDA's three bulk-substance categories, and the HHS draft policy creates no rights for any person [2][3][4].